Description: 

Rysem (Semaglutide) Tablets, for oral use, contain semaglutide, a GLP-1 receptor agonist. The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. Furthermore, semaglutide is modified in position 8 to provide stabilization against degradation by the enzyme dipeptidyl-peptidase 4 (DPP-4). A minor modification was made in position 34 to ensure the attachment of only one fatty di-acid. The molecular formula of Semaglutide is CHaNO

Generic:

Semaglutide

QUALITATIVE AND QUANTITATIVE COMPOSITION

Rysem (Semaglutide) is available for oral administration as:
Rysem Tablet 3mg Each tablet contains:
Semaglutide…3mg
Innovator’s Specs
Rysem Tablet 7mg Each tablet contains:
Semaglutide.. 7mg
Innovator’s Specs
Rysem Tablet 14mg
Each tablet contains:
Semaglutide… 14mg